Japanese and US pharma majors Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) say they have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments.
Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (AD). Perhaps surprisingly, shares of Biogen dipped 2.35% to$330.20 by mid-morning trading today.
Phase III data for aducanumab is expected in late 2019 or early 2020. This "could be one of the first disease-modifying drugs to reach the market," Goldman Sachs analyst Terence Flynn wrote in a note to clients back in the summer. Mr Flynn envisages peak sales of $12 billion for aducanumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze